| Iain H Kalfas, MD | |
|
9500 Euclid Ave, Cleveland, OH 44195-0001 | |
| (800) 223-2273 | |
| Not Available |
| Full Name | Iain H Kalfas |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 42 Years |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932165180 | NPI | - | NPPES |
| 0727904 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35049593K (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Hillcrest Hospital | Mayfield heights, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
| Menorah Park Center For Senior Living | 3577469444 | 187 |
News Archive
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
Though skin cancer is deadly to male fish, it also has one perk: The black melanoma splotches arise from attractive natural markings that lure female mates. A new study published in the Proceedings of the National Academy of Sciences this week shows that the melanoma gene can be conserved in swordtail fish because of its beneficial role in sexual selection.
BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI's antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.
Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.
› Verified 8 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
Though skin cancer is deadly to male fish, it also has one perk: The black melanoma splotches arise from attractive natural markings that lure female mates. A new study published in the Proceedings of the National Academy of Sciences this week shows that the melanoma gene can be conserved in swordtail fish because of its beneficial role in sexual selection.
BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI's antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.
Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Iain H Kalfas, MD 6000 W Creek Rd, Suite 10, Independence, OH 44131-2139 Ph: (800) 223-2273 | Iain H Kalfas, MD 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: (800) 223-2273 |
News Archive
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
Though skin cancer is deadly to male fish, it also has one perk: The black melanoma splotches arise from attractive natural markings that lure female mates. A new study published in the Proceedings of the National Academy of Sciences this week shows that the melanoma gene can be conserved in swordtail fish because of its beneficial role in sexual selection.
BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI's antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.
Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.
› Verified 8 days ago
Jonathan J Rasouli, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic 9500 Euclid Ave S-40, Cleveland, OH 44195 Phone: 216-444-9580 | |
Eric Herring, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-3472 | |
Prakash Kotagal, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 | |
Dr. Gene Henry Barnett, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-5381 | |
Dr. Sara Alsulaimani, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave # Na-23, Cleveland, OH 44195 Phone: 440-226-1283 | |
Alan R Cohen, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-3004 Fax: 440-449-1555 | |
Dr. Seth Alan Hoffer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave., Dept Of Neurosurgery, Univ Hospitals Of Cleveland, Cleveland, OH 44106 Phone: 216-844-3004 Fax: 216-844-3014 |